Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01554514 · ClinicalTrials.gov registry record · Phase 2
Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01554514 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 19 participants.
The verdict
NCT01554514, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
Thrombotic thrombocytopenic purpura (TTP) is a disease characterized by small blood clots throughout the body that can damage major organs and cause death. TTP is treated with plasma exchange (also called "plasmapheresis"). Patients who do not respond initially to plasma exchange often are helped by later treatment with rituximab. The purpose of this study is to see whether combining low doses of rituximab with plasma exchange will help patients get better sooner and reduce the chance of getting TTP again.
Interventions
- BIOLOGICAL rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-08 |
| Est. Completion | 2020-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01554514
The ClinicalTrials.gov registry entry for NCT01554514 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT01554514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01554514 about?
NCT01554514 is a clinical study titled "Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura". Thrombotic thrombocytopenic purpura (TTP) is a disease characterized by small blood clots throughout the body that can damage major organs and cause death. TTP is treated with plasma exchange (also called "plasmapheresis"). Patients who do not respond initially to plasma exchange often are helped by...
What is the current status of trial NCT01554514?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-08. Estimated completion is 2020-02-14.
What interventions are being tested in trial NCT01554514?
The interventions under investigation include: rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01554514?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.